PanGIA Biotech to Present AI-Enabled Urine-Based Prostate Cancer Diagnostic at ASCO 2025

PanGIA Biotech, a leading company in urine-based, AI-driven diagnostics for early cancer detection, has announced that an abstract co-authored with researchers from Entopsis Inc. and the Genetics Institute of America will be presented at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO). The conference, which will take place from May 30 to June 3, 2025, in Chicago, Illinois, is a prestigious gathering of oncology professionals and researchers. The abstract, titled "Development and Validation of an AI-Enabled Prediction of Prostate Cancer (PCa) Using Urine-Based Liquid Biopsy" (Abstract #3080), has been accepted for presentation during the poster session on Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. This session will highlight cutting-edge research that is shaping the future of cancer therapy and diagnostics. The presentation showcases the results of a collaborative effort centered around PanGIA’s innovative, AI-driven, urine-based diagnostic platform. By integrating advanced biomolecular pattern analysis with machine learning, the research aims to develop scalable, non-invasive solutions that can significantly improve the early detection and management of prostate cancer. Holly Magliochetti, CEO of PanGIA Biotech, expressed her excitement about the presentation, stating, "This acceptance reflects our commitment to developing non-invasive, scalable diagnostics that leverage the potential of liquid biopsy innovation. Our goal is to advance technologies that enable earlier cancer detection and enhance access to care on a global scale." The abstract's co-authors include experts from PanGIA Biotech, Entopsis Inc., and the Genetics Institute of America, underscoring the interdisciplinary nature of the project and the strength of the collaboration. PanGIA Biotech is at the forefront of using AI to transform disease detection and management. The PanGIA® platform, powered by machine learning, analyzes biomolecular patterns in urine to provide accurate and timely diagnostic insights. This technology is particularly valuable for detecting cancers at their earliest stages, such as Stage 1, where treatment outcomes are often most favorable. The company’s innovations are backed by extensive peer-reviewed research and are protected by a portfolio of patents. These patents ensure that PanGIA Biotech can continue to develop and refine its diagnostic tools on a global scale. With a strong focus on research and innovation, PanGIA Biotech aims to revolutionize the field of disease detection and improve healthcare worldwide. For more information about PanGIA Biotech and its groundbreaking work, visit www.PanGIABiotech.com.